ORTX

Orchard Therapeutics plc (ORTX) | Rumor.io

Orchard Therapeutics

ORTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ORTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Oct 5

Orchard Therapeutics plc ($ORTX) is being acquired by Kyowa Kirin for $16.00/ADS plus an additional CVR of $1.00/ADS in a deal worth approximately $478M.
This acquisition marks a significant event for the company, with some investors reporting seven-figure profits and others expressing relief after a long period of market volatility.
The deal may also have implications for other gene therapy companies, with some analysts suggesting that it could set a precedent for future acquisitions in the sector.

Generated by AI

Sentiment

Of the messages about ORTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	66.67% -33.33
Bearish	—	—	0% -100	33.33% +33.33

Bullish· Oct 5

$ORTX has been acquired by Japan's Kyowa Kirin in a deal worth $16 per share, representing a 200% gain for some investors.
The acquisition could be a sign of things to come for other gene therapy companies, such as $AVRO, which may also see increased value recognition in the rare disease and gene therapy space.
Despite the sector's recent struggles, $ORTX's buyout price of $16 per share is significantly higher than its price just last month, indicating that the smart money has exited the sector, leaving opportunities for long-term investors.

Bearish· Oct 5

$ORTX has experienced a significant decline of around -86% from its IPO price to its buyout price, raising concerns about the company's valuation and performance.
The acquisition of $ORTX for $478 million is lower than its IPO valuation of $1.4 billion, indicating a substantial loss in value for investors who held onto the stock.
The company's poor performance has led to a significant decline in its stock price, from $200 to $4, and ultimately to $16, with many investors expressing frustration and disappointment with the investment.

Generated by AI

Topics

Of the messages about ORTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Oct 5

Orchard Therapeutics (ORTX) is being acquired by Kyowa Kirin for $16 per American Depositary Share (ADS) in cash, plus an additional contingent value right (CVR) of $1.00 per ADS.
The total value of the deal is approximately $478 million, with the potential for an additional $1.00 CVR to be paid for a total of $17.00 per ADS if certain conditions are met.
ORTX shares surged 95.5% in pre-market trading after the announcement, with the company's gene therapy business and leadership in the rare disease space being cited as key factors in the acquisition.

Technical Analysis· Feb 9

ORTX gapped up on multiple news catalysts, showing good price action on decent volume in the premarket, with a premarket high at 8.45.
The stock broke through a double top and a major trend line resistance, with daily Stochastics indicating plenty of room to run.
Daily resistance is not until $10-$10.50, with a potential target price of $15.

Generated by AI

Community

Of the messages about ORTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	45.45%
Newcomers	—	—	100%	54.55%

Regulars· Oct 5

The regulars are celebrating a 95% premarket rocket after Orchard Therapeutics was acquired by Gene-Therapy Specialist's acquisition, with some taking profits and others holding on to their positions.
The acquisition price of $16 per American Depositary Share (ADS) in cash, plus an additional contingent value right (CVR) of $1.00 per ADS, is being compared to the stock's IPO price and historical performance.
Some regulars are lamenting the opportunity cost of not having invested in Orchard Therapeutics earlier, with one participant noting they would be 332% up and in 1st place in a contest if they had picked the stock.

Newcomers· Oct 5

The acquisition of Orchard Therapeutics plc (ORTX) by Kyowa Kirin has sparked discussion among newcomers, with some noting the 100% premium price and wondering if this is a sign of value recognition in the rare disease and gene therapy space.
Newcomers are focusing on the potential for future gains, with one user sharing their experience of suffering with ORTX for two years and making their first buy above the buyout price, and another hoping for a seven-figure gain.
The acquisition has also led to comparisons with other gene therapy companies, with some users expressing frustration at the lack of action in beaten-down stocks, such as PASG, which trades flat despite the sector's potential.

Generated by AI

News

AI startup CEO pleaded guilty in US to trading on insider tips from lawyers

2mo agoReuters

Also Discussed

Investors talking about ORTX also mention

#	Name	Attention
1	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
2	Cartesian Therapeutics, Inc.RNAC	0%0
3	Regenxbio Inc.RGNX	0%+0
4	ETNB - 89bio, Inc.	——
5	Pharming Group N.V. ADRPHAR	0%+0
6	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
7	FRLN - Freeline Therapeutics Holdings plc	——
8	GTHX - G1 Therapeutics, Inc.	——
9	BLUE - bluebird bio, Inc.	——
10	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01